



February 9, 2015

## **Biocept, Inc. Prices \$10,000,000 Public Offering**

SAN DIEGO, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock and warrants to purchase up to an aggregate of 8,000,000 shares of its common stock at a combined offering price of \$1.25. The warrants will have a per share exercise price of \$1.56, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are expected to be approximately \$10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of common stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is expected to close on February 13, 2015, subject to customary closing conditions.

Aegis Capital Corp. and Feltl and Company, Inc. are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on February 9, 2015.

The offering will be made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained, when available, by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: [prospectus@aegiscap.com](mailto:prospectus@aegiscap.com). Investors may also obtain these documents at no cost by visiting the SEC's website at <http://www.sec.gov>.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Biocept**

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA or ctDNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR<sup>TM</sup> test for breast cancer and OncoCEE-LU<sup>TM</sup> for non-small cell lung cancer and OncoCEE- GA<sup>TM</sup> for Gastric Cancer and plans to introduce additional CLIA validated tests for breast, lung, colorectal, melanoma, prostate and other solid tumors based on its proprietary technology platforms over the coming months.

CONTACT: Corporate Communications Contact:

For Media:

Melanie Sollid-Penton, The Ruth Group

[msollid@theruthgroup.com](mailto:msollid@theruthgroup.com)

(646) 536-7023

For Investors:

David Burke, The Ruth Group

[dburke@theruthgroup.com](mailto:dburke@theruthgroup.com)

(646) 536-7009



Source: Biocept, Inc.

News Provided by Acquire Media